Allulose as a Safer Sugar Substitute for Sickle Cell Disease Patients
Author Information
Author(s): Choi Seong Su, Kim Eun Ji, Shin Su-Kyung, Lee Ji-Yoon, Han Ji Won, Kwon Eun-Young, Bae Heekyong R., Baker Peter R. II
Primary Institution: Kyungpook National University
Hypothesis
Can allulose mitigate thrombotic risks in sickle cell disease patients compared to erythritol?
Conclusion
Allulose may offer a safer alternative to erythritol by reducing platelet activation and improving mitochondrial function in individuals at risk of thrombotic events.
Supporting Evidence
- Allulose significantly reduced platelet aggregation compared to erythritol.
- Gene expression analysis showed downregulation of pro-thrombotic pathways in the allulose group.
- Allulose improved mitochondrial function in mice fed a high-fat diet.
- Erythritol exacerbated platelet activation in high-fat diet models.
- Chronic inflammation from high-fat diets increases thrombotic risks.
- Allulose may modulate critical pathways associated with platelet function.
- Platelet gene expression in sickle cell disease patients was analyzed.
- Allulose offers potential benefits for individuals with sickle cell disease.
Takeaway
Allulose is a type of sugar that can help keep blood from clotting too much, which is important for people with certain health problems.
Methodology
The study involved feeding mice different diets and analyzing gene expression related to platelet activation and mitochondrial function.
Potential Biases
Potential biases in animal model applicability to human conditions.
Limitations
The study was conducted on mice, and further research is needed in human clinical trials.
Participant Demographics
32 male C57BL/6J mice, 4 weeks old.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website